Dementia: Clinical Background

Transcription

1 2 Dementia: Clinical Background 2.1 What Is Dementia? Contents 2.1 What Is Dementia? Prevalence and Incidence Prevalence Incidence sological Approach Genetic/Protein Classification Clinical and Pathological Uncertainty Differential Diagnosis Diagnostic Evaluation Multidisciplinary Integration Suggested Reading Dementia refers to a clinical syndrome rather than a disease. Dementia is usually defined as an acquired condition involving multiple cognitive impairments that are sufficient to interfere with activities of daily living. It is usually but not necessarily progressive. Memory impairment is one of the most common deficits, but other domains such as language, praxis, visualperceptive and most notably executive functions are often involved. With increasing loss of function due to these cognitive problems, there is progressive difficulty with activities of daily living. Many of the diseases that cause dementia have a relentlessly progressive course with an insidious onset; many have long durations (e.g. 5 1 years from diagnosis) and relatively prolonged end stage period where all selfcare and independence is lost. Dementia places tremendous burdens on patients, their families and carers and on health and social care systems. The most important causes of dementia have an agerelated incidence. As a result, the prevalence and societal costs of dementia are predicted to rise dramatically over the coming decades. 2.2 Prevalence and Incidence Of all diseases associated with age, dementia is the fastest growing entity (Fig. 2.1) Prevalence In 2, prevalence data of 11 European populationbased studies were pooled to obtain stable estimates of F. Barkhof et al., Neuroimaging in Dementia, DOI: 1.17/ _2, SpringerVerlag Berlin Heidelberg 211 5

2 6 2 Dementia: Clinical Background 4 Cases/1 3 Dementia 2 Stroke 1 Parkinson Age (years) Fig. 2.1 Prevalence of three ageassociated syndromes. Dementia shows the highest increase in numbers with advancing age (Eurodem) prevalence of dementia in the elderly (>65 years). Agestandardized prevalence was 6.4% for dementia (all causes), 4.4% for and 1.6% for VaD. Prevalence of dementia was higher in women than in men and nearly doubled with every 5 years increase of age: from.8% in the age group years to 28.5% over the age of 9 years (Fig. 2.2). Prevalence rates for dementia have been compared among 12 populationbased European studies Incidence 5 Prevalence per 1 Crude prevalence rates varied between 5.9% (Italy, the Coun selice study) and 9.4% (the Netherlands, Rotterdam study). Again, an almost exponential increase with age and a female excess mostly after age 75 was described, independent of country. As the age distribution of the Western population shifts, the rapid increase of the prevalence of dementia with increasing age means that both the number of affected individuals and the affected proportion of the total population are increasing. This will be most prominent in Europe, where the median age of the population is higher than in any other part of the world. A consensus conference in 25 under the auspices of Alzheimer Disease International estimated that 24.3 million people worldwide suffer from dementia, with 4.6 million new cases of dementia every year (one new case every 7 s) (Ferri et al. 25). A recent update by I in 29 estimated that 35.6 million people worldwide will be living with dementia in 21. This number was estimated to nearly double every 2 years, to 65.7 million in 23, and million in 25 (www. alz.co.uk). Much of the increase is clearly attributable to increases in the numbers of people with dementia in low and middle income countries. Rates of increase are not uniform and are driven by the population structure and lifeexpectancy changes; numbers in developed countries are forecasted to increase by 1% between 21 and 24, but by more than 3% in India, China and their south Asian and western Pacific neighbours. Men Women Fig. 2.2 Prevalence rates of dementia among men and women after the age of 65. (After Lobo et al. (2) Neurology 54(11 Suppl 5):S4 S9) In the same collaborative effort that pooled prevalence data of European studies, data on incidence of dementia of eight populationbased European studies were compared and pooled. In total, there were 42,996 personyears of followup with 835 new dementia cases. Of these, 6 7% were diagnosed with and 15 2% with VaD. Incidence rates of dementia increased exponentially with age from 2.4 per 1, personyears in the age group to 7.2 per 1, personyears in the 9 age group. Rates among women were higher, especially above the age of 8 (Fig. 2.3). The rates continue to increase with age in women, whereas the increase plateaus in men at age 85.

3 7 Incidence rates per 1 personyears 2.3 sological Approach 1 men women Fig. 2.3 Pooled incidence rates of dementia by sex. (Data from Fratiglioni et al. (2) Neurology 54(11 Suppl 5):S1 S15) 2.3 sological Approach As mentioned above, dementia is a syndrome, not a disease, and has many and varied causes. The diagnostic workup is meant to identify the underlying cause with a particular emphasis on picking up treatable conditions. Diagnosis is critically dependent on careful history taking from patient and informant followed by clinical and cognitive examination supported by ancillary investigations, of which neuroimaging is one of the most important. The a priori chance of a particular disease being present is dependent on age. The younger the patient, the greater the chance that one of a wide range of underlying pathologies is the cause of the cognitive problems. Diseases like FTD and HD tend to occur more often before the age of 7; genetic forms of almost exclusively occur at young ages and rare metabolic causes are more likely in early adulthood (see Table 2.1). In the older patient,, DLB and vascular disease are by far the most common pathologies. Mixed disease is very common: notably, with vascular disease has been shown to be the most prevalent in postmortem series of older individuals (>85 years). The nosological approach is facilitated by the use of clinical criteria, which are detailed in the remaining chapters of this book, where the diseases Table 2.1 Differential diagnostic considerations in a patient presenting with dementia at young age (arbitrarily defined as onset before age 65). te the wide variety of diseases in this age group and the particular emphasis on the use of imaging Disease MRI findings Clinical clues Additional tests Posterior cingulate atrophy, medial temporal atrophy Family history, visuospatial and apraxia > memory CSF (abeta and tau); FDGPET; amyloid PET FTLD Frontotemporal atrophy Temporal atrophy (asymmetrical or symmetrical) Family history, language, behaviour FDGPET CBD Frontoparietal atrophy; may be asymmetrical Asymmetrical Parkinsonism, dyspraxia and myocolonus; alien limb CSF; Dopamine imaging SVD Strategic infarcts, lacunes, WMH TIA; stroke Vascular risk factors Vasculitis WMH, patchy enhancement, multifocal diffusion restriction TIA, multifocal ESR and CRP elevation; CSF, DSA, serology MS Disseminated WM lesions, black holes; Gadenhancement Relapses; other neurological findings CSF oligoclonal bands CJD Abnormal DWI basal ganglia or neocortex Myoclonus; cerebellar ataxia EEG, CSF tau and 1433protein Paraneoplastic or limbic encephalitis Temporal lobe lesions; thalamic swelling Subacute onset; other neurological findings CSF antibodies Infectious WM lesions, enhancement Fever, HIV, Lues Serology, CSF, culture Metabolic WM lesions, GM lesions, lactate in spectroscopy, diffusion restriction Strokelike episode CSF, serology, muscle biopsy, genetics Source: Modified from Ridha B, Josephs KA (26) Neurologist 12:2 13 te the wide variety of diseases and the particular emphasis on the use of imaging. For abbreviations see list on page XV

4 8 2 Dementia: Clinical Background Table 2.2 Listing of the clinical criteria for the various dementia syndromes Dementia type Presenting Criteria symptom Year published Imaging included Memory NINCDSRDA DSM IV Dubois Yes, MRI/PET VaD Memory Memory Unspec Dysexecutive NINDSAIREN DSM IV SCDTC SIVD Yes, CT/MRI Yes, CT/MRI Yes, MRI DLB Fluctuating, Executive Dysfunction McKeith 25 SPECT and MRI FT(L)D Behaviour, Language Neary McKhann Supportive CJD sporadic Various Masters 1979 CJD variant Psychiatric Will 2 Yes, MRI PSP Falls, Parkinsonism Litvan Williams CBD Limb Dyspraxia Boxer 26 NPH Gait Vanneste 2 Yes, CT/MRI Huntington Chorea CAG repeats 1993 MSA Parkinsonism Gilman 28 MRI, PET supportive The table illustrates that for some diseases in time neuroimaging features have been added to the strictly clinical features. For abbreviations see list on page XV presenting with dementia are discussed. In Table 2.2, the main disease categories and their published clinical criteria are listed with the use of imaging highlighted. From the table, it may be inferred that for the majority of diseases, no specific imaging criteria have been formulated; however, it is also notable that more recent revisions of criteria are increasingly including imaging (for positive as well as negative predictive value) Genetic/Protein Classification Several genes have been implicated in the origin of dementia syndromes. Some diseases are almost exclusively genetic, like HD, while in, genetic forms account for <5% of all cases. While the gene product is known for many of the genes, effective therapy has not evolved. In Table 2.3 the known genes and location are listed Clinical and Pathological Uncertainty Using clinical criteria various levels of diagnostic certainty may be reached. For instance, the NINCDSRDA criteria for probable have a diagnostic sensitivity and specificity compared to the pathological diagnosis, ranging between 5% and 9%, mainly depending on the setting (clinical expertise) and the age of the patients studied. This diagnostic uncertainty applies to other clinical criteria as well. Of note is that when imaging is included in the criteria such as in the NINDSAIREN a higher degree of specificity (>9%) is reached. In general, the use of imaging has shifted from excluding disorders that may mimic a dementia

5 9 2.4 Differential Diagnosis Table 2.3 Genetic causes of dementia Disease/phenotype Gene Gene product Chromosome Age at onset (typical) PSEN 1 PSEN 2 APP Amyloid Amyloid Amyloid variable HCHWA APP Cystatin C BRI2 Amyloid Variant cystatin C ABri and an <65 variable variable CJD, FFI, GSS PRNP Prion protein 2 variable FTD (esp bvftd), CBS, PSP MAPT Tau FTD, PNFA Progranulin, GRN TDP43 ve intranuclear inclusions in neurons BvFTD, FTDMND TARDBP (TDP43); CHMP2B; VCP Idem; Ubiquitin 1, 3, 9 Very variable and rare CASIL tch3 tch protein Huntington s disease IT15 Huntingtin 2 Variable (CAG repeat length) For abbreviations see list on page XV syndrome or may be (surgically) treatable to using it to identify specific abnormalities that may aid the clinician to diagnose underlying disease, i.e. to increase specificity over sensitivity. One has to bear in mind that the ultimate gold standard for diagnosis does not exist. In many criteria, a definite diagnosis is often designated as either being made postmortem or on the basis of genetic information. The former is obviously too late to be helpful in the clinical situation and usually becomes available many years after the first clinical manifestation. The latter may be available during the clinical workup, and probably better serves to inform the clinician about the underlying pathology than anything else. In this respect, certain tau mutations leading to an unexpected clinical diagnosis of or vice versa presenilin mutations with unexpected clinical FTD presentation are particularly informative. However, one has to be careful about generalising from familial to sporadic cases. The future of clinical diagnosis making lies within the realm of making a diagnosis at protein level, regardless of the clinical presentation. Possibly, molecular imaging (e.g. demonstrating amyloid deposition rather than a given clinical presentation) will allow a more rational approach towards disease modifying treatment; other imaging of specific pathological markers (e.g. tau) would be very valuable in differential diagnosis. Until that is possible, clinical and radiological information has to be pooled to make the best possible judgement to enable treatment and management of the patient. 2.4 Differential Diagnosis In the twentieth century the perspective on dementia evolved tremendously. Before 19, there was very little in the way of specific diagnoses, but with much effort from clinicians to recognize subtypes and help from pathologist, geneticists, neuroimagers and others, it is now possible to make a list of differential diagnoses and to have a fair chance of predicting pathology in a number of conditions. Memory deficits, a key feature of the DSM IIIR definition of dementia is no longer essential for dementia and a number of criteria for different diseases causing dementia incorporate the different cognitive profiles expected in the different disorders. This shift in conceptual thinking is illustrated in Table 2.2.

6 Diagnostic Evaluation A full diagnostic evaluation is warranted in every patient who present with cognitive or behavioural complaints. Current EFNS and AAN guidelines stipulate what tests are evidence based and need to be done. Below, the main ancillary investigations are summarised. te that in general the tendency is to move away from excluding other (brain) diseases, towards finding specific clues to make a diagnosis. Imaging has taken the lead in this, followed closely by CSF examinations and to a lesser extent EEG Laboratory Tests These should be used to explore whether the patient has comorbidity, risk factors for dementia, and risk for delirium or has a primary cause for dementia. For this matter, the following tests are generally proposed as mandatory: full blood count and erythrocyte sedimentation rate (ESR), electrolytes, calcium, glucose, renal, liver and thyroid function tests. More extensive tests will be required in individual cases (and places), like serological test for syphilis and vitamin B12 levels, HIV and Borrelia. Patients should be treated for comorbidity, especially thyroid and vitamin B12 deficiency Cerebrospinal Fluid (CSF) Like imaging, CSF provides a window on the brain as biochemical changes, such as extracellular aggregation of beta amyloid in plaques and formation of tau tangles, are reflected in it. A 5% decrease of CSF Ab42 is seen in patients with or MCI in comparison to agematched controls. The decrease has been associated with enhanced Ab42 deposition in the brain. With specificity set at 9% the mean sensitivity is 86% in comparison to normal aging. In the differential diagnosis between and other dementias, CSF Ab42 is only moderately specific, with reduced levels also seen in DLB and to a lesser extent also in FTLD and VaD. CSF tau levels are on average increased 2 3 times in and MCI in comparison to controls. Tau is 2 Dementia: Clinical Background thought to reflect the amount of neuronal degeneration in chronic neurodegenerative disorders. With specificity set at 9%, mean sensitivity is 81% for. Elevation of CSF tau is also observed in CJD and after acute stroke; in VaD and FTLD it may also be elevated. The concentration of CSF phosphorylated tau (e.g. ptau181 or ptau231) reflects the phosphorylated state of tau protein, and thus the formation of tangles. CSF levels of ptau in patients can be increased by an order of magnitude compared to controls. Increased levels of ptau are considered to be more specific for (Box 2.1). Assessment of 1433 protein in the sporadic form of CJD has a sensitivity and specificity well above 9%. False positive test results have been noted in patients with encephalitis, cerebral infarcts, metastases, paraneoplastic syndromes and rapidly progressive, making it likely that the protein is a marker of brain cell death rather than for CJD ElectroEncephalography (EEG) Generalised slowing of background rhythm on EEG is a frequent finding in and DLB. These changes are not specific for and can also be found in other diffuse encephalopathies (Box 2.2). In FTD patients, the EEG is generally normal. Typical sharp wave complexes are relatively specific for CJD, particularly for the sporadic form. Another possible important finding is temporal epileptic activity which can cause transient epileptic amnesia, a rare cause of memory deficits. In the Box 2.2 the main EEG findings in various dementias are listed. Box 2.1 Levels of CSF markers in some dementias Total tau Ptau181 Ab142 / DLB / V / / FTLD / / CJD rmal aging mildly elevated, elevated, strongly elevated, normal CSF markers in the most prevalent dementia syndromes. (Courtesy of Dr. N.S.M. Schoonenboom). For abbreviations see list on page XV

7 11 Suggested Reading Box 2.2 EEG characterisctics in the most prevalent dementia syndromes. te that for FTLD in particular EEG is normal, while in CJD it has the highest diagnostic yield FTLD VaD Delirium DLB CJD Decreased alpha rhythm Decreased alpha reactivity Asymmetric alpha rhythm Theta waves Temporal slow waves Focal abnormalities Sharp waves Periodic discharges FIRDA never occurring, incidental, sometimes, frequent, almost always, FIRDA frontal intermittent delta activity. (Courtesy Prof C.J. Stam) 2.5 Multidisciplinary Integration The diagnosis of a patient with (suspicion of) dementia may require input from many disciplines: clinicians (e.g. geriatricians, neurologists, psychiatrists), psychologists, neurophysiologists as well as radiologists and nuclear medicine specialists. The increasing need for an earlier and more specific diagnosis to guide management and treatment poses a burden on the diagnostic skills of the team involved. The appropriate use of neuroimaging covered in this book may help to advance diagnosis and alleviate burden for the patient and carer. This book aims to take an approach that fits with clinical reality that one is presented with patients with clinical and imaging features rather than diagnoses. The arrangement of the book aims to help the reader to move from imaging and clinical features to a diagnosis; and to be accessible to all those seeking to improve diagnosis in dementia. Suggested Reading Dubois B, Feldman HH, Jacova C, DeKosky ST, BarbergerGateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, óbrien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (27) Research criteria for the diagnosis of Alzheimer s disease: revising the NINCDS RDA criteria. Lancet Neurol 6: Ferri CP, Prince M, Brayne C et al (25) Global prevalence of dementia: a Delphi consensus study. Lancet 366: Harvey RJ, SkeltonRobinson M, Rossor MN (23) The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 74(9): Hort J, O Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P, on behalf of the EFNS scientist panel on dementia (21) EFNS guidelines for the diagnosis and management of Alzheimer s disease. Eur J Neurol 17(1): Knopman DS, DeKosky ST, Cummings JL et al (21) Practice parameter: diagnosis of dementia (an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: Scheltens P, Fox N, Barkhof F, De Carli C (22) Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 1:13 21 Schott JM, Fox NC, Rossor MN (22) Genetics of the dementias. J Neurol Neurosurg Psychiatry 73:ii27 ii31

8